Head-To-Head Comparison: NeurAxis (NASDAQ:NRXS) versus ResMed (NYSE:RMD)

NeurAxis (NASDAQ:NRXS – Get Free Report) and ResMed (NYSE:RMD – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NeurAxis and ResMed, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeurAxis 0 1 1 0 2.50
ResMed 0 11 7 0 2.39

NeurAxis currently has a consensus target price of $13.00, indicating a potential upside of 139.85%. ResMed has a consensus target price of $253.69, indicating a potential upside of 5.90%. Given NeurAxis’ stronger consensus rating and higher possible upside, equities analysts clearly believe NeurAxis is more favorable than ResMed.

Insider & Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 21.1% of NeurAxis shares are held by insiders. Comparatively, 0.6% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

NeurAxis has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Earnings & Valuation

This table compares NeurAxis and ResMed”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeurAxis $6.53 million 10.42 -$14.63 million ($1.06) -5.11
ResMed $5.65 billion 5.96 $1.52 billion $10.98 21.82

ResMed has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NeurAxis and ResMed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeurAxis -492.76% N/A -641.25%
ResMed 27.79% 26.42% 19.43%

Summary

ResMed beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

About ResMed

(Get Free Report)

ResMed is a medical technology company that develops products and software for people with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its devices include continuous positive airway pressure (CPAP) and bilevel machines, ventilators and related masks and accessories. The company also provides cloud-connected software for managing sleep and respiratory care, along with digital tools used by home medical equipment providers and post-acute care organizations.

Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.